Actively Recruiting
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Led by AdventHealth · Updated on 2024-10-24
30
Participants Needed
1
Research Sites
159 weeks
Total Duration
On this page
Sponsors
A
AdventHealth
Lead Sponsor
B
Blue Earth Diagnostics
Collaborating Sponsor
AI-Summary
What this Trial Is About
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
CONDITIONS
Official Title
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
- An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
You will not qualify if you...
- Patients who are planned to have an x-ray contrast agent or other PET radiotracer less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan.
- Patients currently receiving Androgen Deprivation Therapy (ADT).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
AdventHealth
Orlando, Florida, United States, 32804
Actively Recruiting
Research Team
A
AdventHealth AdventHealth Oncology Research
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here